Literature DB >> 17407855

Statin wars following coronary revascularization - evidence-based clinical practice?

Bernard Prigent.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17407855      PMCID： PMC2647892          DOI： 10.1016/s0828-282x(07)70765-1

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN： 0828-282X            Impact factor:   5.223


× No keyword cloud information.
  9 in total

1.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors:  G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

3.  Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada.

Authors:  J Frohlich; G Fodor; R McPherson; J Genest; N Langner
Journal:  Can J Cardiol       Date:  1998-04       Impact factor: 5.223

4.  National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).

Authors: 
Journal:  Circulation       Date:  1994-03       Impact factor: 29.690

5.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

Authors:  Terje R Pedersen; Ole Faergeman; John J P Kastelein; Anders G Olsson; Matti J Tikkanen; Ingar Holme; Mogens Lytken Larsen; Fredrik S Bendiksen; Christina Lindahl; Michael Szarek; John Tsai
Journal:  JAMA       Date:  2005-11-16       Impact factor: 56.272

6.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

Authors:  P Jones; S Kafonek; I Laurora; D Hunninghake
Journal:  Am J Cardiol       Date:  1998-03-01       Impact factor: 2.778

7.  Statin wars following coronary revascularization--evidence-based clinical practice?

Authors:  James M Brophy; Vania Costa
Journal:  Can J Cardiol       Date:  2006-01       Impact factor: 5.223

8.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

9.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.